MaxCyte (MXCT) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Apr, 2026Voting matters and shareholder proposals
Election of three nominees as Class II directors: Patrick J. Balthrop, Cynthia Collins, and Stanley C. Erck for the board.
Ratification of CohnReznick LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Additional business may be addressed if properly brought before the meeting or any adjournment.
Board of directors and corporate governance
Board recommends voting in favor of all director nominees and the auditor ratification.
Audit committee and external auditor matters
Audit Committee has selected CohnReznick LLP as the independent auditor for the upcoming fiscal year.
Shareholders are asked to ratify this selection at the annual meeting.
Partial view of Summaries dataset, powered by Quartr API
Latest events from MaxCyte
- Election of directors and auditor ratification highlight governance and compensation practices.MXCT
Proxy filing29 Apr 2026 - 2025 revenue fell 15%, but cost cuts and new launches set up a back-half 2026 recovery.MXCT
Q4 202527 Mar 2026 - Scalable cell engineering platform drives recurring revenue and supports diverse clinical programs.MXCT
Corporate presentation25 Mar 2026 - SPL portfolio growth drives clinical milestones, commercial launches, and strong revenue potential.MXCT
Investor presentation25 Mar 2026 - Q2 2024 revenue up 15% to $10.4M, SPL revenue surges, net loss narrows, guidance raised.MXCT
Q2 20242 Feb 2026 - Non-viral cell engineering drives new curative therapies, fueling growth and high-margin expansion.MXCT
The 44th Annual William Blair Growth Stock Conference1 Feb 2026 - Q3 revenue up 2% to $8.2M, core revenue up 23%, six new SPLs signed, and guidance raised.MXCT
Q3 202416 Jan 2026 - Non-viral, ex vivo cell therapy growth and SPL expansion drive strong financial outlook.MXCT
Stifel 2024 Healthcare Conference14 Jan 2026 - Validated cell therapy platform drives growth, SPL expansion, and strong financial performance.MXCT
Stephens 26th Annual Investment Conference | NASH202413 Jan 2026